Get Free Trial
News & Analysis
On The Fly
About The Fly
Instant updates and real-time market news.
VBL Therapeutics management to meet with Roth Capital
Meeting to be held in San Francisco on October 6 hosted by Roth Capital.
VBL Therapeutics mentioned positively at Roth Capital
VBL Therapeutics thyroid study points in right direction, says Roth Capital
Roth Capital analyst Joseph Pantginis notes that VBL Therapeutics has announced positive follow-up overall survival data from the Phase 2 thyroid cancer study with VB-111. The analyst believes VB-111 represents a "strong potential option" for patients with recurrent glioblastoma and looks forward to clinical progress in the Phase 3 rGBM study. Pantginis projects upside from future clinical updates, expansion opportunities for new indications as well as partnership potential for VB-111. He reiterates a Buy rating and $17 price target on the shares.
TODAY'S FREE FLY STORIES